Table 2.
Summary of Clinical Trial Results
Clinical trial | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
COVE | AZD1222 | ENSEMBLE | PREVENT-19 | VAT00008 (stage 2)a | ||||||
Treatment group | Placebo | mRNA- 1273 | Placebo | AZD1222 | Placebo | Ad26.COV2.S | Placebo | NVX-CoV2373 | Placebo | CoV2 preS dTM-AS03 (D614+ B.1.351) |
Study population, No. | ||||||||||
Full-analysisb | 15 166 | 15 180 | 10 797 | 21 583 | 21892 | 21 896 | 9961 | 19 907 | 6450 | 6472 |
Per protocolc | 14164 | 14287 | 8550 | 17 662 | 19398 | 19 400 | 8140 | 17312 | 5680 | 5736 |
End points, No. of events | ||||||||||
Primary: virologically confirmed symptomatic COVID-19 | 744 | 55 | 184 | 141 | 895 | 443 | 63 | 14 | 89 | 32 |
Secondary: severe COVID-19 | 106 | 2 | 10 | 1 | 176 | 46 | 4 | 0 | 2 | 3 |
Abbreviation: mRNA, messenger RNA.
Results from stage 2 report on the bivalent vaccine data only.
Indicates cohort of participants who had undergone randomization and received at least 1 dose of placebo or vaccine.
Indicates cohort of participants who were SARS-CoV-2 negative before the first dose and received the complete number of doses, with no major Protocol deviation.